This National Cancer Institute (NCI) grant is for establishing a Canine Cancer Immunotherapy Network (K9CIN) to advance canine cancer research. It aims to support clinical studies in pet dogs with spontaneous tumors, utilizing immunotherapeutic agents and novel drug combinations. The grant also funds correlative laboratory studies to characterize and understand the cellular and molecular mechanisms of anti-tumor responses. Priority areas include therapeutic modulation of the tumor microenvironment (TME) or direct immune-mediated cancer destruction, often combined with other therapies like radiation or adoptive immune cell therapies. Awardees are expected to share therapeutic agents, specimens, and protocols to standardize and validate data within the collaborative network.
Opportunity ID: 334907
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | RFA-CA-21-050 |
| Funding Opportunity Title: | Canine Cancer Immunotherapy Network (K9CIN; U01 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.393 — Cancer Cause and Prevention Research |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 27, 2021 |
| Last Updated Date: | Jul 27, 2021 |
| Original Closing Date for Applications: | Sep 27, 2021 |
| Current Closing Date for Applications: | Sep 27, 2021 |
| Archive Date: | Nov 02, 2021 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | – |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Independent school districts Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education City or township governments State governments County governments Native American tribal organizations (other than Federally recognized tribal governments) Native American tribal governments (Federally recognized) Public housing authorities/Indian housing authorities Small businesses Others (see text field entitled “Additional Information on Eligibility” for clarification) Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Private institutions of higher education Public and State controlled institutions of higher education |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | Through this Funding Opportunity Announcement (FOA), the National Cancer Institute (NCI) will support canine clinical studies using immunotherapeutic agents and novel drug combinations together with laboratory correlative studies that seek to characterize and understand the cellular and molecular mechanisms that determine anti-tumor responses (or non-responses) in pet dogs with spontaneous tumors. The goal is to create a network of laboratories and canine clinical trial sites. The proposed clinical studies must include therapeutic modulation of the tumor microenvironment (TME) or must elicit direct immune-mediated destruction of cancer. Priority attributes include: combinations of immunotherapy/TME-modulating therapy with radiation therapy or other therapies (e.g., targeted therapies, chemotherapies or other immunotherapies); adoptive immune cell therapies such as CAR T-cell therapies or NK cell therapies; studies including longitudinal biopsy; and studies including tumor DNA sequencing and transcriptomics in pet dogs treated with immunotherapeutic agents. Within the network, awardees are expected to share therapeutic agents, specimens, and laboratory and clinical protocols in order to standardize and validate data generated. A companion funding opportunity will support a coordinating center that will aid in the development, standardization, harmonization, and conduct of the clinical and laboratory studies, as well as data management and statistical support across the funded U01 sites (see U24 award supported under companion RFA-CA-21-051). |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/rfa-files/RFA-CA-21-050.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
grantsinfo@nih.gov Email:grantsinfo@nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
There are no related documents on this grant.
Packages
| Agency Contact Information: | NIH OER Webmaster grantsinfo@nih.gov Email: grantsinfo@nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-F | Use for due dates on or before January 24, 2022 | PKG00268339 | Aug 27, 2021 | Jan 24, 2022 | View |
Package 1
Mandatory forms
334907 RR_SF424_2_0-2.0.pdf
334907 PHS398_CoverPageSupplement_5_0-5.0.pdf
334907 RR_OtherProjectInfo_1_4-1.4.pdf
334907 PerformanceSite_2_0-2.0.pdf
334907 RR_KeyPersonExpanded_2_0-2.0.pdf
334907 PHS398_ResearchPlan_4_0-4.0.pdf
334907 PHSHumanSubjectsAndClinicalTrialsInfo_2_0-2.0.pdf
Optional forms
334907 RR_Budget_1_4-1.4.pdf
334907 RR_SubawardBudget30_1_4-1.4.pdf
334907 PHS398_ModularBudget_1_2-1.2.pdf
334907 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
